Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Recruiting

Phase 3

DepemokimabDepemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

Sponsor:

GlaxoSmithKline

Code:

NCT05334368

Conditions

Hypereosinophilic Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Depemokimab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-16. This information was provided to ClinicalTrials.gov by GlaxoSmithKline on 2025-04-22.